NCT00840801已完成3 期
SINGLE-BLIND, RANDOMIZED, PHASE III B STUDY IN CHILDREN AGED 1 - 11 YEARS TO INVESTIGATE THE IMMUNOGENICITY, SAFETY AND INTERCHANGEABILITY OF TWO TICK-BORNE ENCEPHALITIS (TBE) VACCINES ADMINISTERED ACCORDING TO A CONVENTIONAL SCHEDULE
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 302
- 试验地点
- 13
- 主要终点
- Seropositivity Rate as Determined by Neutralization Test (NT) 28 Days After the Second Vaccination
研究概览
简要总结
The objective of this study is to assess the immunogenicity, safety and interchangeability of two different TBE vaccines in children aged 1-11 years, the first and second vaccination with either FSME-IMMUN 0.25ml Junior or Encepur 0.25ml Children and the third vaccination with FSME-IMMUN 0.25 ml Junior only, administered according to the conventional schedule (0, 28 and 360 days).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 1 Year 至 11 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female children will be eligible for participation in this study if:
- •they are aged >= 1 years (from the 1st birthday) to 11 years (to the last day before the 12th birthday) at screening;
- •their parents / legal guardians provide written informed consent;
- •children provide written assent to the study according to age and capacity of understanding;
- •their parents/guardians understand the nature of the clinical study and will comply with the requirements of the protocol (e.g., completion of the Subject Diary, return for follow-up visits);
- •they are generally healthy, (i.e. the physician would have no reservations vaccinating with a TBE vaccine outside the scope of a clinical study);
- •provide a negative pregnancy test result at the first medical examination (if the subject is a female and capable of bearing children).
排除标准
- •Subjects will be excluded from participation if:
- •they have a history of any previous TBE vaccination;
- •they have a history of TBE infection;
- •they have a history of infection with other flaviviruses;
- •they have a history of vaccination against yellow fever and/or Japanese B encephalitis;
- •they have a history of severe allergic reactions, in particular a known sensitivity or allergy to any components of the vaccines;
- •they are suffering from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions;
- •they have received any blood product or immunoglobulins within 90 days prior to study entry;
- •they are known to be Human Immunodeficiency Virus (HIV) positive (an HIV test is not required specifically for the purpose of this study);
- •they have a functional or surgical asplenia;
- •they have a rash or other dermatological condition at the injection site which could interfere with injection site reaction evaluation;
- •they were administered an investigational product within six weeks prior to study start or are concurrently participating in another clinical study that includes the administration of an investigational product;
- •they are pregnant or breastfeeding (if a female subject);
- •they or their parents/legal guardian(s) are in a dependent relationship with the study investigator or with a study team member. Dependent relationship includes close relatives (i.e., children or grandchildren, partner/spouse, siblings) as well as employees of the investigator or site conducting the study.
- •Subjects who have an acute illness with or without elevated body temperature (>=37.5°C) within 3 days prior to the scheduled first vaccination will not be vaccinated. Subjects may be included at a repeat visit provided that (1) the illness has resolved (body temperature < 37.5 °C), (2) the repeat visit is no more than 14 calendar days after the Screening Visit, and (3) the center is still open for recruitment.
- •If subjects have received antipyretics within 4 hours prior to the scheduled time of vaccination, the vaccination should be performed at a later date, as long as the center is still open for recruitment.
- •Subjects who received any live vaccine within 4 weeks or any inactivated vaccine within 2 weeks prior to the scheduled first study vaccination will not be vaccinated until an interval of 4 or 2 weeks, respectively, has passed, provided the center is still open for recruitment.
- •If a subject was bitten by a tick within 4 weeks prior to the scheduled first or second vaccination, the vaccination must be postponed until an interval of 4 weeks has passed.
结局指标
主要结局
Seropositivity Rate as Determined by Neutralization Test (NT) 28 Days After the Second Vaccination
时间窗: 28 days after Vaccination 2
Percentage of participants achieving NT titer greater than or equal to (\>=) 10.
次要结局
- Antibody Response Measured by NT 28 Days After the Second Vaccination, 180 Days After the First Vaccination and 28 Days After the Third Vaccination(28 days after Vaccination 2, 180 days after Vaccination 1, 28 days after Vaccination 3)
- Fold Increase of Antibody Response Measured by ELISA 28 Days After the Second Vaccination, 180 Days After the First Vaccination and 28 Days After the Third Vaccination as Compared to Baseline(28 days after Vaccination 2, 180 days after Vaccination 1, 28 days after Vaccination 3)
- Seropositivity Rate Determined by NT 180 Days After the First Vaccination and 28 Days After the Third Vaccination(180 days after the Vaccination 1, 28 days after the Vaccination 3)
- Frequency and Severity of Systemic Reactions Occurring After Second Vaccination(Within 28 days after Vaccination 2)
- Frequency and Severity of Adverse Events (AE) Observed Before the Third Vaccination(Part A: Within 28 days after Vaccination 1 and Vaccination 2, Part B: 28 days after Vaccination 2 to before Vaccination 3)
- Fold Increase of Antibody Response Measured by NT 28 Days After the Second Vaccination, 180 Days After the First Vaccination and 28 Days After the Third Vaccination as Compared to Baseline(28 days after Vaccination 2, 180 days after Vaccination 1, 28 days after Vaccination 3)
- Seropositivity Rate Determined by ELISA 28 Days After the Second Vaccination, 180 Days After the First Vaccination and 28 Days After the Third Vaccination(28 days after Vaccination 2, 180 days after the Vaccination 1, 28 days after the Vaccination 3)
- Frequency and Severity of Systemic Reactions Occurring After First Vaccination(Within 28 days after Vaccination 1)
- Antibody Response Measured by ELISA 28 Days After the Second Vaccination, 180 Days After the First Vaccination and 28 Days After the Third Vaccination(28 days after Vaccination 2, 180 days after Vaccination 1, 28 days after Vaccination 3)
- Frequency and Severity of Systemic Reactions Occurring After Third Vaccination(Within 28 days after Vaccination 3)
- Frequency and Severity of Injection Site Reactions Occurring After the Second Vaccination(Within 6 days of Vaccination 2)
- Frequency and Severity of Injection Site Reactions Occurring After the First Vaccination(Within 6 days of Vaccination 1)
- Frequency and Severity of Injection Site Reactions Occurring After the Third Vaccination(Within 6 days of Vaccination 3)
- Frequency and Severity of Adverse Events (AE) Observed After the Third Vaccination(Within 28 days after Vaccination 3)
研究者
研究点 (13)
Loading locations...
相似试验
已完成
2 期
Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005InfluenzaNCT00161811Alachua Government Services, Inc.1,400
已完成
2 期
A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan AdultsShigella Sonnei InfectionNCT02676895GlaxoSmithKline74
已完成
1 期
Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)Pneumococcal InfectionNCT04665050Merck Sharp & Dohme LLC102
已完成
3 期
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy ToddlersMeningococcal MeningitisMeaslesMumpsRubellaVaricellaNCT00384397Sanofi Pasteur, a Sanofi Company1,128
已完成
2 期
Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US AdultsDengueNCT00350337U.S. Army Medical Research and Development Command86